Pharmacokinetic Responses of Rabeprazole

In gain to the conflicting findings in the eradication rates of H. pylori communication, the pharmacodynamic effects of rabeprazole in patients who are CYP2C19 poor metabolizers and in those who are extensive metabolizers have been controversial.
One abstraction showed that the pharmacodynamic effects (e.g., intragastric pH) after a base hit oral dose of Aciphex 20 mg were higher in poor metabolizers than in extensive metabolizers.
However, after 7 days of administering Aciphex 20 mg/day, another chemical group of authors showed that the gastric prevention by rabeprazole is fencesitter of CYP2C19 genetic constitution.
In a different knowledge base, in which the participants took Aciphex 20 mg/day, the intragastric pH was significantly higher in CYP2C19 poor metabolizers than in extensive metabolizers on day 1 of dosing.
This is a part of article Pharmacokinetic Responses of Rabeprazole Taken from "Generic Aciphex (Rabeprazole) Review" Information Blog